NCT04750239View on ClinicalTrials.gov

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

April 8, 2022

Study Completion Date

April 8, 2022

Conditions
SCLC
Interventions
DRUG

Nivatrotamab

Anti GD2×CD3 monoclonal bi-specific antibody

Trial Locations (7)

15232

UPMC Hillman Cancer Center, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

30332

Emory University, Atlanta

33612

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute - Tennessee Oncology, Nashville

48202

Henry Ford Hospital, Detroit

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
lead

Y-mAbs Therapeutics

INDUSTRY